INTRODUCTION

Palliated single ventricle anatomy imposes unique physiologic limitations that increase the risk for cardiac and end organ failure. Patients with failing univentricular circulation often have very high systemic venous pressures as a result of the superimposition of the trans-pulmonary pressure gradient on elevated ventricular end-diastolic pressure, with increased risk of cardiac cirrhosis and end stage liver disease. Here we present the case of a 14-year-old male, with failed bidirectional Glenn circulation and cardiac cirrhosis, who required a combined heart-liver transplant (CHLT). Informed consent from the patient’s legal guardian was obtained for this case report.

CASE REPORT

The patient had double inlet single left ventricle with L-transposition of the great arteries (Figure 1), palliated with pulmonary artery banding at 3 months of age, and subsequent bidirectional Glenn at 10 months of age. At age 22 months, he underwent septation of his double inlet single left ventricle and pulmonary arterioplasty rather than complete Fontan cavo-pulmonary reconstruction (Figure 2). He required pacemaker placement for sick sinus syndrome, but remained at NYHA class 3 functional status. At age 11, he was listed for heart transplantation secondary to congestive heart failure with disseminated systemic venous hypertension. His longstanding Glenn physiology and venous hypertension was associated with extensive systemic to pulmonary collateral formation and worsening hypoxemia secondary to veno-arterial admixture, requiring multiple catheter based interventions for collateral occlusion. These veno-arterial shunts contributed to increased cyanosis and reduced myocardial performance. Pretransplant cardiac catheterization revealed elevated Glenn pressures within the superior vena cava (17 mmHg), main pulmonary artery (22/18, mean 20 mmHg), left pulmonary artery (20/16, mean 19 mmHg), and right pulmonary artery (20/18, mean 19 mmHg). The right atrial pressure was significantly elevated (19 mmHg), consistent with pressure elevations in the hypoplastic right ventricle (24/0, mean14 mmHg). Left ventricular end diastolic pressure was also elevated (17 mmHg). He was found to have portal hypertension with elevated hepatic venous wedge pressures (20 mmHg within the right hepatic lobe and 21 mmHg within the left hepatic lobe) which were similar to measured right atrial pressures. While awaiting heart transplantation, he developed cirrhosis confirmed via liver biopsy. Due to the end stage nature of his heart and liver disease he was listed for combined organ transplantation. His pretransplant course was further complicated by pulmonary hemorrhage from ruptured paratracheal varices. These varices extended from the proximal trachea to the mainstem bronchi, and were treated with trans-catheter coiling. He also experienced gastrointestinal bleeding secondary to large (grade III) esophageal varices that required banding. He spent a protracted period of time on the transplant list awaiting a suitable donor.

On the day of transplant, intraoperative monitoring included...
central venous pressure prior to liver transplantation. Post-
CPB TEE demonstrated good left ventricular systolic function,
mildly reduced right ventricular systolic function, trivial mitral
regurgitation, and no tricuspid regurgitation. Heparin effect was
fully reversed with protamine and hemostasis achieved.

With the patient’s sternum left open, and after hemodynamic
and hemostatic stabilization, transplantation of the liver began.
Venovenous bypass (VVB) was used during the anhepatic phase.
Venous inflow was provided by cannulation of the left superficial
saphenous vein, and return provided through the indwelling
right atrial venous cannula used during the cardiac transplant.
Flow on systemic VVB was approximately 1.3 L/min and was
further augmented to over 2 L/min with addition of portal
venous blood to the VVB circuit. Complete caval replacement
technique utilizing the donor IVC graft followed by portal venous
reperfusion was performed for liver allograft implantation.
Cold ischemic time for the donor liver was approximately 480
minutes. Reperfusion was tolerated well without hemodynamic
instability, arrhythmia or reperfusion syndrome and the patient
was removed from VVB on continued inotropic support with
epinephrine (0.08 mcg/kg/min) and milrinone (1 mcg/kg/min).
CVP ranged from 5 to 7 mmHg, and LAP from 2 to 4 mmHg during
reconstruction of the hepatic artery and bile duct. Intraoperative
coaagulation was assessed with thromboelastography (TEG®,
Haemoscope Corp. IL, USA), activated clotting times, and heparin
concentrations (Hepcon® HMS, Medtronic Inc. MN, USA). A total
of 11 units of packed red blood cells, 24 units of fresh frozen
plasma, 18 units of cryoprecipitate, 3 single donor pheresed units
of platelets, and 2 liters of cell saver blood were administered
throughout the combined procedure. After ensuring satisfactory
hemostasis and hemodynamics, the sternum and abdomen were
closed sequentially. The patient tolerated the procedure well,
and was transferred to the intensive care unit with mechanical
ventilation and inotropic support. The intraoperative monitoring
strategy and hemodynamic management were continued in the
postoperative period.

**DISCUSSION**

Although uncommon in the pediatrics, CHLT has classically
been performed for inherited metabolic diseases. One such
example is familial hypercholesterolemia in which a defect
in hepatic cholesterol metabolism results in early advanced
atherosclerosis [1,2]. Another is familial amyloidosis in which
heart failure results from defective protein folding within the
myocardiocytes [3,4]. In these diseases, CHLT is required to
replace the damaged heart and reverse the metabolic defect
with a normal liver. Cardiac failure from complex congenital
heart disease with secondary liver failure has represented a rare
indication for pediatric CHLT [5].

Single ventricle anatomy as occurs in the patients with
hypoplastic left heart syndrome requires sequential palliative
procedures to create functional series circulation. Palliation is
necessary for survival beyond infancy, but long-term morbidity
and early mortality remain. Complications of failed single-ventricle
physiology include congestive heart failure, arrhythmias, venous
hypertension, plastic bronchitis, protein losing enteropathy, and
liver dysfunction [6]. Heart transplantation may be curative
in such cases. Single ventricle palliation is associated with an

---

**Figure 2**

Electrocardiogram, pulse oximetry, non-invasive and invasive
arterial blood pressure, central venous pressure (CVP), and two-
site (cerebral and somatic) near-infrared spectroscopy (NIRS)
(Somanetics INVOS, Troy, MI). Anesthesia was induced with
intravenous midazolam, fentanyl, and sevoflurane and maintained
with fentanyl and isoflurane. Cisatricurium was administered
for neuromuscular blockade. Oral endotracheal intubation
was performed without fiberoptic guidance as pretransplant
flexible bronchoscopy revealed complete decompression of his
tracheal varices. Intravenous access included a right internal
jugular vein introducer (8.5 Fr), a triple lumen left subclavian
central venous line (7.5 Fr), and bilateral antecubital fossa rapid
infusion catheters (7.5 Fr and 4.5 Fr). Pressure in the superior
vena cava (SVC) varied from 18-25 mmHg throughout the pre-
bypass period. Transesophageal echocardiography (TEE) was
also utilized.

Orthotopic heart transplantation with cardiopulmonary
pulmonary bypass (CPB) was performed first in order
to minimize donor myocardial ischemic time. Tranexamic acid was
administered as antifibrinolytic therapy per protocol: 50 mg/
kg IV loading dose, 50 mg/kg in the CPB pump prime, and 15
mg/kg continuous IV infusion. The patient’s bidirectional Glenn
anastomosis was taken down prior to donor heart implantation.

Donor heart ischemic time was 217 minutes. Following
successful reanimation of the donor heart the patient separated
from CPB on epinephrine (0.1 mcg/kg/min) and milrinone
(0.75 mcg/kg/min) infusions, a vasoactive strategy targeting
low pulmonary and systemic vascular resistance and high
contractility. The CVP ranged from 6 to 8 mmHg, and left atrial
pressure (LAP) from 4 to 6 mmHg. The patient’s systemic
venous hypertension was markedly improved following cardiac
transplantation. Ventilatory management after liberation from
CPB included inhaled nitric oxide (NO) to reduce right ventricular
afterload, optimize right ventricular function and minimize
increased risk of nonalcoholic cirrhosis [7]. Most commonly this occurs in patients with Fontan physiology, however extensive liver fibrosis has also been shown prior to Fontan completion [8].

The incidence of cirrhosis in single ventricle patients appears to be increasing. Krieger et al noted a 173% increase in the incidence of admissions for cirrhosis in single ventricle patients from 1998 to 2009. When compared to single ventricle patients without cirrhosis, those with cirrhosis were more likely to have concurrent congestive heart failure. This evidence suggests that failed single ventricle physiology with concurrent cardiac and hepatic failure is likely to be an emerging indication for pediatric CHLT.

Anesthetic considerations are complex for CHLT in patients with palliated single ventricle heart disease. A comprehensive preoperative evaluation is critical to assess for associated comorbidities (arrhythmias, pulmonary collaterals, pulmonary hypertension, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, etc), and to optimize preoperative health status. Massive transfusion is to be expected during CHLT and adequate blood product availability must be confirmed preoperatively. Intraoperatively, large bore peripheral intravenous access is required, as are intra-arterial and central venous pressure monitoring. Different anesthetic induction strategies are commonly employed for isolated heart or liver transplantation. End stage cardiac disease is associated with reduced cardiac output and prolonged intravenous induction times. Induction for heart transplantation is usually involves premedication followed by a gradual balanced induction including a combination of intravenous (opiates, benzodiazepines and/or etomidate) and volatile agents. Rapid sequence inductions tend to be avoided due to concerns for profound hemodynamic lability, particularly in patients with palliated univentricular hearts. In contrast, end stage liver disease is associated with increased cardiac output and shortened intravenous induction times. Typically, a rapid sequence intravenous induction without excessive premedication is recommended for liver transplantation to minimize risk of aspiration. These differences must be considered and addressed during CHLT. In this instance, we utilized premedication and a balanced induction technique with cricoid pressure in order to preserve cardiac output and perfusion while attempting to reduce aspiration risk. Additional concerns relate to risks associated with instrumentation of the trachea and esophagus in patients with variceal disease. Proper endotracheal tube placement may require fiberoptic guidance in patients with tracheal varices. Similarly, esophageal varices must be considered prior to TEE and gastric tube placement in patients with esophageal varices.

Surgical techniques employed for CHLT include: 1) implantation of both organs on CPB, with an additional portal venous cannula; 2) heart implantation on CPB, and liver implantation on VVB, with an additional portal venous cannula; 3) heart implantation on CPB and liver implantation without bypass. When choosing a method for implantation of the donor organs, the team must be cognizant of the divergent physiologic needs of each donor organ. Acute right heart failure is common following heart transplantation and may be exacerbated by elevated recipient pulmonary artery pressures, pulmonary vein pressures, and interstitial lung disease. In recipients with pre-existing pulmonary hypertension, the transplanted right ventricle may exhibit restrictive physiology with preload dependence and require pulmonary vasodilator (inhaled nitric oxide, intravenous milrinone, etc.) therapy to compensate for increased right ventricular afterload. The right ventricle is at risk for coronary ischemia and concurrent systemic vasopressor administration may be needed to maintain adequate right coronary artery perfusion pressure. In patients with pulmonary arteriovenous malformations, arterial hypoxemia occurs at low transpulmonary pressure gradients. Both right heart dysfunction and veno-arterial admixture will improve with inhaled nitric oxide. In contrast to the donor heart, the optimal environment following donor liver implantation is one of low systemic venous pressure to limit hepatic venous congestion. These competing goals must be recognized and dynamically prioritized during combined organ transplantation.

In this case we chose heart implantation on CPB and liver implantation on VVB. We were concerned that the unconditioned donor right ventricle would fail without the preload preservation provided via VVB, yet the need for full anticoagulation with CPB during liver transplantation would be undesirable. We were able to reverse heparin fully following CPB, permitting optimal hemostasis prior liver transplantation. A heparin-bonded circuit was used for VVB, negating the need for additional anticoagulation. VVB support allowed for preload preservation and reduced vasoactive medication requirements during liver implantation. This also provided vital time for donor right heart recovery following ischemia such that the systemic venous pressures following liver reperfusion were acceptable with central venous pressures generally less 10 mmHg. This strategy ultimately proved successful as the both grafts functioned well following implantation.

In this example, failed univentricular physiology with end stage heart and liver disease was treated with combined heart-liver transplantation. As growing numbers of single ventricle patients survive staged palliation pathways with ongoing physiologic limitation, it is likely that many will require combined organ transplantation and management expertise in the perioperative care of congenital heart disease, cardiac transplantation, and hepatic transplantation.

REFERENCES


5. Hollander SA, Reinhartz O, Maeda K, Hurwitz M, N Rosenthal D,

